The nation of Zimbabwe has declined a significant US health deal valued at 367 million US dollars (£272m) over five years over Washington's request for confidential biological samples.
The decision became public following a official document from December was disclosed, revealing that President Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesperson later stated that the US was seeking health data for research and profit while refused to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further negotiations to secure a agreement acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Context
This rejection follows a comparable situation in neighbouring Kenya, where a high court halted a related health funding agreement following concerns were raised about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was seeking government-to-government agreements to enhance transparency and accountability.
As per statements, Sixteen nations in Africa have to date signed similar health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered significant advantages for Zimbabwean communities, especially the 1.2 million presently on HIV treatment through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our nation would supply the raw materials for medical research without any assurance that the resulting innovations would be available to our population should a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral deals were disrupting structures already established via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to further dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that talks need to persist since a large portion of the nation's HIV programmes were funded by foreign aid.
"Where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the continuing challenges between accepting much-needed international aid and safeguarding local interests in an ever more data-driven world.